R&D Breaking into the global pharmaceutical market In 2022, pharma is truly a global industry, and innovation can come from anywhere.
Partner Content Partner Content Registration opens for SMi’s 4th Annual Ophthalmic Drugs Con... Registration opens for Ophthalmic Drugs Conference
News Nuvalent chases after Nuvation in ROS1 lung cancer New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
